What is the latest on Venetoclax? (https://www.myeloma.org/videos/latest-venetoclax)

In this week's video, Dr. Durie discusses what effect a new treatment can have on your myeloma protein levels, and when it can be time to consider changing your treatment regimen with your doctor.

BOTTOM LINE:
Venetoclax will move forward as a “targeted” precision medicine approach for patients with the t(11;14) abnormality.

 

 

Author
Dr. Brian GM Durie (https://www.myeloma.org/Brian-Durie-md)
Related Videos
Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/videos/venetoclax-plus-carfilzomib-dexamethasone-patients-relapsedrefractory-multiple-myeloma)
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with RR multiple myeloma (https://www.myeloma.org/videos/phase-2-study-venetoclax-plus-carfilzomib-dexamethasone-patients-rr-multiple-myeloma)
Square Image Media
title card for Ask Dr Durie What is the latest on Venetoclax
Video
Series
Ask Dr. Durie (https://www.myeloma.org/taxonomy/term/19)
Old Id
2338
Old references
1807,1815
Tags
Venetoclax (https://www.myeloma.org/taxonomy/term/80)

Ask a Question

Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (mailto:[email protected]) (Please do not send email attachments or lab reports.). 

 

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.

 

Source URL: https://www.myeloma.org/videos/latest-venetoclax